Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE:LLY) entered into a collaboration and license agreement. This agreement grants Lilly exclusive, worldwide rights to research, develop, manufacture, ...

Eli Lilly's portfolio, both within and outside its core area, makes the stock attractive. However, a recent move Eli Lilly made reveals an underrated reason why the stock has attractive prospects.

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

They worry tariffs, aimed at bringing drug production to the United States, could instead drive companies out of business ...

Antimicrobial-resistant (AMR) “superbugs” contribute to more than 4.5 million deaths globally per year and threaten to make ...

WestEnd Advisors LLC grew its position in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing ...

Mounjaro and Wegovy are two of the biggest names in the world of weight-loss drugs but it's been unclear which is more effective until now. But the jabs have gone head-to-head in an effectiveness ...

The last couple of quarters have been very favorable for Eli Lilly and Company (NYSE:LLY) and its position in the obesity and adjacent markets. The main competitor Novo Nordisk A/S (NVO ...